These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 27493190)

  • 1. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.
    Mohanraju P; Makarova KS; Zetsche B; Zhang F; Koonin EV; van der Oost J
    Science; 2016 Aug; 353(6299):aad5147. PubMed ID: 27493190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas: Adapting to change.
    Jackson SA; McKenzie RE; Fagerlund RD; Kieper SN; Fineran PC; Brouns SJ
    Science; 2017 Apr; 356(6333):. PubMed ID: 28385959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation.
    Bhaya D; Davison M; Barrangou R
    Annu Rev Genet; 2011; 45():273-97. PubMed ID: 22060043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems.
    Hwang S; Maxwell KL
    CRISPR J; 2019 Feb; 2(1):23-30. PubMed ID: 31021234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering.
    Wright AV; Nuñez JK; Doudna JA
    Cell; 2016 Jan; 164(1-2):29-44. PubMed ID: 26771484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling the structural and mechanistic basis of CRISPR-Cas systems.
    van der Oost J; Westra ER; Jackson RN; Wiedenheft B
    Nat Rev Microbiol; 2014 Jul; 12(7):479-92. PubMed ID: 24909109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-canonical inhibition strategies and structural basis of anti-CRISPR proteins targeting type I CRISPR-Cas systems.
    Yin P; Zhang Y; Yang L; Feng Y
    J Mol Biol; 2023 Apr; 435(7):167996. PubMed ID: 36754343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral diversity threshold for adaptive immunity in prokaryotes.
    Weinberger AD; Wolf YI; Lobkovsky AE; Gilmore MS; Koonin EV
    mBio; 2012 Dec; 3(6):e00456-12. PubMed ID: 23221803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobile Genetic Elements and Evolution of CRISPR-Cas Systems: All the Way There and Back.
    Koonin EV; Makarova KS
    Genome Biol Evol; 2017 Oct; 9(10):2812-2825. PubMed ID: 28985291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
    Liu Q; Zhang H; Huang X
    FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. It is unclear how important CRISPR-Cas systems are for protecting natural populations of bacteria against infections by mobile genetic elements.
    Westra ER; Levin BR
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):27777-27785. PubMed ID: 33122438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling and enhancing CRISPR systems.
    Shivram H; Cress BF; Knott GJ; Doudna JA
    Nat Chem Biol; 2021 Jan; 17(1):10-19. PubMed ID: 33328654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type II anti-CRISPR proteins as a new tool for synthetic biology.
    Zhang Y; Marchisio MA
    RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical organizations and epistatic interactions of CRISPRs and cas clusters in genomes and their mobile genetic elements.
    Bernheim A; Bikard D; Touchon M; Rocha EPC
    Nucleic Acids Res; 2020 Jan; 48(2):748-760. PubMed ID: 31745554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ecology and evolution of microbial CRISPR-Cas adaptive immune systems.
    Westra ER; van Houte S; Gandon S; Whitaker R
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20190101. PubMed ID: 30905294
    [No Abstract]   [Full Text] [Related]  

  • 17. CRISPR-Cas systems: beyond adaptive immunity.
    Westra ER; Buckling A; Fineran PC
    Nat Rev Microbiol; 2014 May; 12(5):317-26. PubMed ID: 24704746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CRISPR-Cas systems by mobile genetic elements.
    Sontheimer EJ; Davidson AR
    Curr Opin Microbiol; 2017 Jun; 37():120-127. PubMed ID: 28668720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophages suppress CRISPR-Cas immunity using RNA-based anti-CRISPRs.
    Camara-Wilpert S; Mayo-Muñoz D; Russel J; Fagerlund RD; Madsen JS; Fineran PC; Sørensen SJ; Pinilla-Redondo R
    Nature; 2023 Nov; 623(7987):601-607. PubMed ID: 37853129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five big mysteries about CRISPR's origins.
    Ledford H
    Nature; 2017 Jan; 541(7637):280-282. PubMed ID: 28102279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.